

NERVGEN PHARMA CORP.

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

(Expressed in Canadian dollars)

(Unaudited)

	For the 3 Months Ended June 30, 2019 \$	For the 3 Months Ended June 30, 2018 \$	For the 6 Months Ended June 30, 2019 \$	For the 6 Months Ended June 30, 2018 \$
Operating expenses				
Research and development (Note 12)	883,920	7,963	2,999,772	7,963
General and administration (Note 12)	685,519	56,387	1,593,237	67,012
Total operating expenses	1,569,439	64,350	4,593,009	74,975
Interest income	(44,389)	-	(46,412)	-
Net loss and comprehensive loss for the period	(1,525,050)	(64,350)	(4,546,597)	(74,975)
Basic and diluted net loss per share	(0.06)	(0.04)	(0.19)	(0.08)
Weighted average common shares outstanding (Note 9)	27,637,373	1,829,496	23,498,068	919,803

The accompanying notes are an integral part of these condensed consolidated interim financial statements